Vincentage posts phase 3 win for oral weight-loss drug VCT220

Vincentage Pharma said its once-daily oral GLP-1 candidate, VCT220, met primary endpoints in a pivotal Phase 3 trial in overweight or obese adults in China, reporting mean weight loss of 12.2% and 12.4% at 52 weeks in the 120 mg and 160 mg groups, versus 1.3% with placebo. The Chengdu-based company said the study enrolled 840 adults, began in November 2024, and supported plans to file a near-term New Drug Application with China’s National Medical Products Administration for chronic weight management. Vincentage and its partner Corxel have positioned VCT220 as a non-peptide oral option that doesn’t require food or water restrictions, refrigeration, or light-protected storage. (globenewswire.com)

Why it matters: While this is a human obesity story rather than a veterinary product development update, it’s relevant to veterinary professionals because it shows how fast the oral GLP-1 field is moving, especially around convenience, adherence, and chronic weight management. Those same themes increasingly shape pet parent expectations, investor interest, and future translational conversations around obesity care, even though VCT220 itself is being developed for people, not animals. The topline readout also adds to evidence from Vincentage’s earlier Phase 2 program, which showed weight loss by week 16 along with improvements in measured cardiometabolic markers such as blood pressure and liver enzymes, with mostly mild to moderate gastrointestinal adverse events. (corxelbio.com)

What to watch: Watch for the NMPA filing in China and for Corxel’s U.S. Phase 2 readout for CX11, the ex-China version of VCT220, later in 2026. (globenewswire.com)